Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuping Sun

Showing results (341-350 of 349) with videos related to

Pageof 35
Sort By:
You have reached the last page of results.This site can display upto 349 results.
Cancer Cell|April 24, 2026
JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1<sup>G2032R</sup> resistance mutation in NSCLC: The first-in-human phase 1 trialYuxiang Ma, Jinhui Xue, Fangfang Gao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 7, 2022
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 TrialAnwen Xiong, Shengxiang Ren, Huaimin Liu, et al.
Nature Medicine|July 16, 2025
CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trialJia Liu, Jianwei Yang, Yuping Sun, et al.
Nature Communications|May 14, 2015
Genome-wide association analysis identifies three new risk loci for gout arthritis in Han ChineseChanggui Li, Zhiqiang Li, Shiguo Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 21, 2021
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational TrialShun Lu, Qiming Wang, Guojun Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|June 28, 2020
A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA studyShun Lu, Gongyan Chen, Yuping Sun, et al.
Cancer Communications (London, England)|July 17, 2024
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)Shun Lu, Xiaorong Dong, Hong Jian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2022
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R MutationsShun Lu, Xiaorong Dong, Hong Jian, et al.
Imeta|December 31, 2025
<i>iMeta</i> Conference 2025: Creating high-impact international journalsZhihao Zhu, Lin Zhang, Xiaofang Yao, et al.
Pageof 35

Showing results (341-350 of 349) with videos related to

Sort By:
Pageof 35
You have reached the last page of results.This site can display upto 349 results.
Cancer Cell|April 24, 2026
JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1<sup>G2032R</sup> resistance mutation in NSCLC: The first-in-human phase 1 trialYuxiang Ma, Jinhui Xue, Fangfang Gao, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 7, 2022
Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 TrialAnwen Xiong, Shengxiang Ren, Huaimin Liu, et al.
Nature Medicine|July 16, 2025
CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trialJia Liu, Jianwei Yang, Yuping Sun, et al.
Nature Communications|May 14, 2015
Genome-wide association analysis identifies three new risk loci for gout arthritis in Han ChineseChanggui Li, Zhiqiang Li, Shiguo Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 21, 2021
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational TrialShun Lu, Qiming Wang, Guojun Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|June 28, 2020
A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA studyShun Lu, Gongyan Chen, Yuping Sun, et al.
Cancer Communications (London, England)|July 17, 2024
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)Shun Lu, Xiaorong Dong, Hong Jian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2022
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With <i>EGFR</i> Exon 19 Deletion or L858R MutationsShun Lu, Xiaorong Dong, Hong Jian, et al.
Imeta|December 31, 2025
<i>iMeta</i> Conference 2025: Creating high-impact international journalsZhihao Zhu, Lin Zhang, Xiaofang Yao, et al.
Pageof 35